The BCR has also been shown to continue to undergo somatic hypermutation (SHM) following resolution of acute COVID‐19, and this maturation is associated with improved affinity for the antigen and neutralization potency; however, it is not known whether this differs with disease severity.11, 15. This evidence concerns the gene BCR and COVID-19.